GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)

OBJECTIVE: To determine the efficacy and safety of intermittent docetaxel chemotherapy guided by circulating methylated glutathione S-transferase Pi-1 (mGSTP1) in men with metastatic castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: GUIDE (NCT04918810) is a randomised, two-arm, non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Conduit, Ciara, Mak, Blossom, Qu, Wenjia, Lulio, Juliana Di, Burder, Ronan, Bressel, Matthias, Cusick, Thomas, Dhillon, Haryana M., Lourenço, Richard De Abreu, Underhill, Craig, Torres, Javier, Crumbaker, Megan, Honeyball, Florian, Linton, Anthony, Allen, Ray, Davis, Ian D., Clark, Susan J., Horvath, Lisa G., Mahon, Kate L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019311/
https://www.ncbi.nlm.nih.gov/pubmed/35465297
http://dx.doi.org/10.1177/17588359221092486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019311/
https://www.ncbi.nlm.nih.gov/pubmed/35465297
http://dx.doi.org/10.1177/17588359221092486

Ejemplares similares